Company overview
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing GRI with another company.
| Daily close (USD) | $1.68 |
| Market capitalization (USD) | $3,672,673.2 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.36 |
No matching rows. Clear the filter to see all records.
Read GRI's valuation metrics
Company size
GRI Bio, Inc. Common Stock's recorded market capitalization is $3,672,673.2. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
GRI's recorded price-to-book ratio is 0.36. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research GRI Bio, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about GRI. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow GRI's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.